Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 13/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9960275 | 0.99 | ESR1 (0.42) | ESR1ESR2GAA | |
| SCHEMBL10169841 | 0.84 | ESR1 (0.45) | ESR1ESR2SLCO1B1 | |
| Hydrochloric Acid SCHEMBL9957531 | 0.83 | ESR1 (0.44) | ESR1ESR2SLCO1B1 | |
| SCHEMBL10169927 | 0.81 | ESR1 (0.47) | ESR1ESR2GAA | |
| SCHEMBL10170736 | 0.80 | ESR1 (0.45) | ESR1ESR2 | |
| SCHEMBL10169839 | 0.79 | ESR1 (0.43) | ESR1 | |
| SCHEMBL9956414 | 0.79 | ESR1 (0.46) | ESR1ESR2 | |
| SCHEMBL10169837 | 0.79 | ESR1 (0.46) | ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL9955635 | 0.78 | ESR1 (0.45) | ESR1ESR2 | |
| Trifluoroacetic Acid SCHEMBL9956822 | 0.76 | ESR1 (0.41) | ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9540361-B2 | N-substituted azetidine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2017-01-10 | — | — | US | disclosed |
| US-9540361-B2 | N-substituted azetidine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2017-01-10 | — | — | US | disclosed |
| US-20160130262-A1 | N-SUBSTITUTED AZETIDINE DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2016-05-12 | — | — | US | disclosed |
| US-20160130262-A1 | N-SUBSTITUTED AZETIDINE DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2016-05-12 | — | — | US | disclosed |
| WO-2012084711-A1 | N-SUBSTITUTED AZETIDINE DERIVATIVES | MSD OSS B.V. (NL) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130262-A1 | N-SUBSTITUTED AZETIDINE DERIVATIVES | ESR2, ESR1, GPER1 | ESR1 2/4885ESR2 1/4885GAA 3828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.